Does antenatal magnesium sulphate given to women at risk of preterm birth between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children? - a randomised controlled trial [ 2012 - 2017 ]

Research Grant

Researchers: Prof Caroline Crowther (Principal investigator) ,  A/Pr Dominic Wilkinson ,  A/Pr Philippa Middleton ,  A/Pr Ross Haslam

Brief description Antenatal magnesium sulphate is recommended prior to preterm birth at less than 30 weeks’ gestation. Whether there are benefits at later gestations is uncertain. This study is assessing whether magnesium sulphate given to women at risk of very preterm birth between 30 to 34 weeks’ gestation increases the chance of their baby surviving without cerebral palsy.

Funding Amount $AUD 2,086,569.55

Funding Scheme Project Grants

Notes Standard Project Grant